HIV Infections
📧 Sign up to get email alerts when something new happens for HIV Infections.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-07-01EMA Withdrawn: Stocrin (efavirenz) — Merck Sharp & Dohme B.V.
EMA has withdrawn Stocrin (efavirenz) from the market in the EU.
-
CLINICAL_TRIALS withdrawal · 2025-08-17Clinical Trial Update: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa [Phase 1, Phase 2]
The Phase 1/2 trial evaluating safety and immunogenicity of VPM1002 vaccination or BCG revaccination for tuberculosis in HIV-infected and un…
-
EMA withdrawal · 2023-09-25EMA Withdrawn: Invirase (saquinavir) — Roche Registration GmbH
The EMA withdrew Invirase (saquinavir) from registration in the EU, with Roche Registration GmbH as the MAH, in March 2023.
-
EMA withdrawal · 2023-04-21EMA Application withdrawn: Raltegravir Viatris (raltegravir potassium) — Viatris Limited
The EMA has withdrawn the application for Raltegravir Viatris (raltegravir potassium) by Viatris Limited for HIV infections.
-
EMA withdrawal · 2023-03-21EMA Withdrawn: Lamivudine/Zidovudine Teva (lamivudine;zidovudine) — Teva Pharma B.V.
The EMA has withdrawn Lamivudine/Zidovudine Teva (lamivudine; zidovudine) from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2023-02-03EMA Expired: Darunavir Krka d.d. (darunavir) — KRKA, d.d., Novo mesto
The EMA lists Darunavir Krka d.d. (darunavir) as expired, indicating cessation of its marketing authorization in the EU.
-
EMA withdrawal · 2022-07-12EMA Withdrawn: Crixivan (indinavir sulfate ethanolate) — Merck Sharp & Dohme B.V.
Crixivan (indinavir sulfate ethanolate) has been withdrawn from EMA marketing authorization.
-
EMA withdrawal · 2020-10-13EMA Withdrawn: Zerit (stavudine) — Bristol-Myers Squibb Pharma EEIG
EMA has withdrawn Zerit (stavudine) for HIV infections; decision dated 13 February 2019.
-
CLINICAL_TRIALS withdrawal · 2019-09-12Clinical Trial Update: Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 [Phase 3]
A Phase 3 trial evaluating vicriviroc added to optimized antiretroviral therapy for HIV/ AIDS was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2019-03-13Clinical Trial Update: Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort [Phase 4]
A Phase 4 trial evaluating ibandronate for osteoporosis in HIV-infected patients was withdrawn.
-
EMA withdrawal · 2017-05-29EMA Withdrawn: Vitekta (elvitegravir) — Gilead Sciences International Ltd
EMA withdrawn status for Vitekta (elvitegravir) by Gilead Sciences International Ltd. Indicates withdrawal of the medicinal product in Europ…
-
CLINICAL_TRIALS withdrawal · 2015-06-04Clinical Trial Update: A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs [NA]
This is a withdrawn clinical trial evaluating whether certain antioxidants and vitamins can keep lactate levels down in patients taking anti…
-
EMA withdrawal · 2014-06-10EMA Withdrawn: Viracept (nelfinavir) — Roche Registration Ltd.
Viracept (nelfinavir) has been withdrawn from the European market by Roche Registration Ltd., with the decision dated 23 January 2013.
-
EMA withdrawal · 2011-06-21EMA Withdrawn: Agenerase (amprenavir) — Glaxo Group Ltd.
Agenerase (amprenavir) has been withdrawn from the market in the EU.
-
EMA withdrawal · 2006-08-07EMA Withdrawn: Fortovase (saquinavir) — Roche Registration Ltd.
Fortovase (saquinavir) has been withdrawn from the European market by Roche Registration Ltd., with the decision dating 20 August 1998.